COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

NCL News Archive

Monday, March 12, 2018

Evaluation of Nanomedicine Drug Release and Pharmacokinetics

The NCL has two Technical Services to measure drug release from nanomedicines—ideal for assessing bioequivalence of complex drugs. These assays are available as a service to nanomedicine developers, apart from NCL’s Assay Cascade application process.

The two assays utilize the Stable Isotope Tracer Ultrafiltration Assay (SITUA), and include:

In vitro drug release in human plasma... View Post

Friday, December 22, 2017

FDA Draft Guidance, "Drug Products, Including Biological Products, that Contain Nanomaterials" open for comment

The FDA recently published a draft guidance document for “Drug Products, Including Biological Products, that Contain Nanomaterials.” The draft guidance document can be downloaded here:

The FDA is requesting public comments on the draft guidance. They are also seeking comment on the... View Post

Friday, November 17, 2017

November 2017 Awardees Announced

Each quarter the NCL accepts the most promising cancer nanomedicine candidates into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and... View Post

Wednesday, November 1, 2017

Characterization of Nanoparticles Intended for Drug Delivery

The NCL has recently published a follow-on book to its Characterization of nanoparticles intended for drug delivery. This second edition book, now available for download or purchase, offers new and updated protocols for sterility and endotoxin testing, surface coating quantitation, ICP-MS of biological matrices, in vitro hematotoxicity and immunotoxicity, as well as in vitro methods for... View Post

Wednesday, November 1, 2017

New Protocols for Surface Characterization

Two new protocols for surface characterization have been published on the NCL Assay Cascade Protocols webpage.

PCC-16 describes PEG quantitation for PEGylated colloidal gold nanoparticles using reversed phase high performance liquid chromatography (RP-HPLC) and charged aerosol detection (CAD). Two different techniques are described in the protocol, and provide a means to quantitate... View Post

Monday, July 10, 2017

New Drug Release Protocol Available

The NCL has just added a new protocol to our Assay Cascade Protocols page to measure drug release from nanomedicines. The protocol, PHA-2, is based off of the recent Journal of Controlled Release publication, Stable isotope method to measure drug release from nanomedicines. Since its publication in late 2015, this assay has gained a lot of attention and has been in high demand at the NCL,... View Post

Monday, July 10, 2017

Inaugural FNLCR Technology Showcase Draws Hundreds

More than 200 science and business professionals from across the region attended the Frederick National Laboratory for Cancer Research’s (FNLCR) Inaugural Technology Showcase event. The program highlighted technologies developed by NCI and FNLCR investigators available for license or other collaborative development. In addition, Frederick city and county officials highlighted partnership... View Post

Wednesday, May 3, 2017

Nanomedicine Award 2017

The European Technology Platform for Nanomedicine (ETPN) and the EU-funded consortium ENATRANS have launched the third edition of the Nanomedicine Award to honor the best international nanomedicine innovations for 2017.

The goal of the Award is to promote and reward two excellent innovative nanomedicine-based solutions that could bring significant benefits to patients, answering unmet... View Post

Wednesday, May 3, 2017

New Innovative Research in Cancer Nanotechnology (IRCN) Funding Opportunity Announcement (R01)

NCI’s Office of Cancer Nanotechnology Research has published a new funding opportunity announcement (FOA) for the Innovative Research in Cancer Nanotechnology (IRCN) initiative, PAR-17-240. All IRCN awards made through this announcement are R01 grants and will be part of the Alliance for Nanotechnology in Cancer network. Due dates are twice per year, with the announcement remaining open until... View Post

Tuesday, April 4, 2017

2017 FNLCR Technology Showcase

The Frederick National Laboratory for Cancer Research (FNLCR) will be hosting a half-day event that will showcase technologies being developed at the National Cancer Institute (NCI) and FNLCR. The event aims to introduce the Frederick community to the regional technology development stakeholders, highlight available resources, as well as to encourage startup company formation, technology... View Post